Navigation Links
Bacterial peptide provides new insight into common tumor suppressor
Date:7/7/2008

Scientists have identified a new antitumor drug that might prove useful in developing treatments for a multiple human cancers. The research, published by Cell Press in the July 8 issue of the journal Cancer Cell, advances the understanding of one of the most frequently disrupted tumor suppressor proteins in human cancer and provides new insight into the regulation of the complex process of cellular protein degradation under normal and pathological conditions.

"The cyclin kinase inhibitor p27kip1 is one of the most frequently dysregulated tumor suppressor proteins in human cancers and it correlates directly with patient prognosis," explains study author Dr. Nisar P. Malek from Hannover Medical School in Germany. "Due to increased turnover, p27kip1 is not sufficiently expressed in many human cancers. Therefore, targeting the p27kip1 degradation machinery might prove beneficial in the treatment of a variety of human malignancies."

Dr. Malek and colleagues had previously shown that stabilization of p27kip1 reduced progression of intestinal cancer. They sought to build on this earlier work by seeking to identify substances that reduce or block p27kip1 turnover and thereby allowing re-expression of the protein in tumor tissues. Using a cell screening assay, the researchers identified the peptide argyrin A, derived from the myxobacterium Archangium gephyra, as a stabilizer of p27kip1 and a potent, broadly acting antitumor drug.

Argyrin A induced apoptosis in cancer cells, prevented new tumor blood vessels from forming and targeted existing tumor blood vessels. Importantly, all antitumor activities of argyrin A depended on expression of p27kip1 and resistance to argyrin A was directly linked to loss of p27kip1. The researchers went on to reveal that the mechanism by which argyrin A reduces turnover of p27kip1 involves inhibition of the 20S proteasome, a complex that is involved in destruction of the majority of cellular proteins.

These findings show that argyrin A is a proteasome inhibitor that prevents turnover of p27kip1 and exerts potent antitumor activities. "The unique properties of argyrin A combined with its high activity at well-tolerated levels make this compound a good candidate for further clinical development," concludes Dr. Malek.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Reuse of Antibacterial Wipes Can Spread Bacteria
2. Scientist study bacterial communities inside us to better understand health and disease
3. Bacterial Infection May Boost SIDS Risk
4. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
5. Do bacterial combinations result in enhanced cytokine production? No!
6. Does Antibacterial Soap Work? At Least One Really Does.
7. Skin Friendly Releases Clinically Proven Hypoallergenic Anti-Bacterial Barrier Lotion
8. Bacterial battle for survival leads to new antibiotic
9. UCF technique promises to aid doctors ability to identify, treat bacterial infections
10. Why recovery from flu may increase odds of bacterial infection
11. Bacterial toxin closes gate on immune response, Penn researchers discover
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces the ... body image mannequin art competition. Selected from 15 submissions from around the nation, the ... the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... 23, 2017 ITL Limited, ( ASX: ITD ), an ... the half year ended 31 December 2016 compared with the previous ... can be viewed here . Highlights ... up 104%) Earnings per share of 2.2 cents ... $17.5m (Dec 2015: $15.7m; up 11%) Profit before ...
(Date:2/23/2017)... GUIYANG, China , 23. Februar 2017 ... Area , eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz ... Beschleunigung der Errichtung einer Innovationsplattform aktiv an der Entwicklung einer ... Continue Reading ... ...
Breaking Medicine Technology: